leadf
logo-loader
viewMydecine Innovations Group Inc
(
OTC:MYCOFFRA:0NFANEO:MYCO
)

Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking Cessation clinical trial

Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) (NEO:MYCO) CEO Joshua Bartch tells Proactive it has partnered with Principal Investigator Dr Matthew Johnson of Johns Hopkins University on a study evaluating the administration of its lead drug candidate MYCO-001, a pure psilocybin from natural fungal sources, with a structured smoking cessation treatment program in nicotine-dependent individuals.

Bartch says Dr Johnson, who has published extensively on the science of psychedelics, has been contracted by Mydecine to complete the phase 2/3 clinical trial of his ongoing research and develop methodologies to better advance future-controlled studies and clinical trials of psychedelics.

Quick facts: Mydecine Innovations Group Inc

Follow
OTC:MYCOF

Price: 0.2758 USD

Market Cap: $65.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Proactive Analyst Ed Stacey looks at Mydecine Innovations

Insight from Proactive analyst Ed Stacey on Mydecine Innovations Group, a biotech and life sciences company which is developing new therapies derived from psychedelics including psilocybin from mushrooms. Read Ed Stacey's latest update

2 weeks ago

2 min read